Leuprolide · source year
8 selected, source-linked Leuprolide records carrying a 2018 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
8 selected records.
2 represented types.
8 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00455689 at 2026-07-30T21:10:02.989Z. Its registry update date was 2018-09-18, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 205054 with status AP dated 2018-08-28, and names leuprolide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00223665 at 2026-07-30T21:10:02.996Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00002597 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-06-14, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00004635 at 2026-07-30T21:11:31.039Z. Its registry update date was 2018-05-22, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01120236 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-02-26, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2018-02667, attributed to FDA and its parent HHS department, on 2018-02-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01116401 at 2026-07-30T21:12:47.405Z. Its registry update date was 2018-01-23, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗